細(xi)胞基因治療整體解(jie)決(jue)方(fang)案

細胞基因治(zhi)(zhi)療是生物醫藥領(ling)域(yu)的前(qian)沿陣地，它通過對細胞或(huo)基因進(jin)行改(gai)造(zao)、修飾、調控，來糾正或(huo)補償因基因缺陷和異(yi)常(chang)引起的疾(ji)病，為傳統療法難以(yi)攻克的疑難病癥(zheng)，如(ru)遺傳性(xing)疾(ji)病、某些癌癥(zheng)、自身免疫性(xing)疾(ji)病等，帶來了新的治(zhi)(zhi)愈希望。

干細(xi)胞(bao)療(liao)法是細(xi)胞(bao)基因治療(liao)的重(zhong)要分支(zhi)。干細(xi)胞(bao)具備自(zi)我更新和多向分化潛能(neng)，能(neng)分化成(cheng)多種(zhong)功能(neng)細(xi)胞(bao)，修(xiu)復受損組(zu)(zu)織(zhi)(zhi)(zhi)和器(qi)官。間充(chong)質干細(xi)胞(bao)（MSC）是其(qi)中備受關注(zhu)的類型，具有(you)免(mian)疫調(diao)節(jie)、抗炎、促進(jin)(jin)組(zu)(zu)織(zhi)(zhi)(zhi)修(xiu)復等(deng)(deng)特性。在(zai)臨床應用(yong)中，MSC 已被(bei)嘗試用(yong)于治療(liao)多種(zhong)疾病(bing)(bing)，如移植物抗宿主病(bing)(bing)、骨關節(jie)炎、心(xin)肌梗死等(deng)(deng)，通(tong)過調(diao)節(jie)免(mian)疫微環境、促進(jin)(jin)組(zu)(zu)織(zhi)(zhi)(zhi)再生等(deng)(deng)機制發揮治療(liao)作(zuo)用(yong)。

誘導多能(neng)干(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)（iPSC）細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)療(liao)法是另一(yi)項(xiang)創新性突破。iPSC 由成體細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)經重編(bian)程獲得(de)，擁有類似(si)胚胎(tai)干(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)的多能(neng)性。它克服了胚胎(tai)干(gan)(gan)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)來源的倫理問題，可(ke)根據(ju)患(huan)者(zhe)自身(shen)細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)定制，降低免(mian)疫排斥(chi)風險(xian)。iPSC 能(neng)分化為各類細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)，用于疾病建模、藥物篩選(xuan)以及細(xi)(xi)(xi)(xi)(xi)胞(bao)(bao)(bao)移植治療(liao)，為帕金森病、糖(tang)尿病等疾病的治療(liao)帶來新曙光。

基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)遞(di)(di)(di)送(song)(song)(song)技術則是細胞基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)治(zhi)(zhi)療(liao)的關(guan)鍵支(zhi)撐。它負責將治(zhi)(zhi)療(liao)性(xing)(xing)(xing)(xing)(xing)基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)安(an)全、效(xiao)(xiao)率(lv)高地(di)遞(di)(di)(di)送(song)(song)(song)至靶細胞。轉染試劑是基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)遞(di)(di)(di)送(song)(song)(song)常用工具之一，通過特定機制將外源基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)導入細胞。基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)遞(di)(di)(di)送(song)(song)(song)技術面臨(lin)遞(di)(di)(di)送(song)(song)(song)效(xiao)(xiao)率(lv)、靶向性(xing)(xing)(xing)(xing)(xing)、安(an)全性(xing)(xing)(xing)(xing)(xing)等挑戰，理想的遞(di)(di)(di)送(song)(song)(song)系統需準確地(di)將基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)遞(di)(di)(di)送(song)(song)(song)至病(bing)(bing)(bing)變細胞，避免(mian)脫靶效(xiao)(xiao)應，同時不引發免(mian)疫反應和毒性(xing)(xing)(xing)(xing)(xing)。病(bing)(bing)(bing)毒載(zai)體（如腺相(xiang)關(guan)病(bing)(bing)(bing)毒載(zai)體）和非病(bing)(bing)(bing)毒載(zai)體（如脂質納米顆粒(li)）是目(mu)前主流(liu)的基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)遞(di)(di)(di)送(song)(song)(song)載(zai)體，科(ke)研人員不斷優(you)化載(zai)體設計，以提升基(ji)(ji)(ji)(ji)(ji)因(yin)(yin)治(zhi)(zhi)療(liao)的有效(xiao)(xiao)性(xing)(xing)(xing)(xing)(xing)和安(an)全性(xing)(xing)(xing)(xing)(xing)。

細胞(bao)基因治(zhi)療(liao)(liao)憑借(jie)干細胞(bao)療(liao)(liao)法、iPSC 細胞(bao)療(liao)(liao)法和基因遞送技術等不斷(duan)發(fa)展，有望為更多難(nan)治(zhi)性疾病提供(gong)治(zhi)愈(yu)方案，變革未來醫學格局。

您也可以 點擊此處 或者從“下載中心”獲取我們的《CGT全線產品》